PositiveID Successfully Tests 12 Different Assays on its Firefly
Dx Prototype System
Company identified all pathogens in less than 20 minutes on its
prototype PCR pathogen detection system
DELRAY BEACH, FL -- June 22, 2015 -- InvestorsHub NewsWire
-- PositiveID Corporation (PositiveID or Company) (OTCQB:
PSID), a developer of biological detection and diagnostics
solutions, announced today that it has now successfully tested 12
different assays on its Firefly Dx breadboard prototype PCR
(polymerase chain reaction) pathogen detection system. Using both
its own as well as third-party assays, Firefly Dx successfully
detected all the pathogens it tested for in less than 20
minutes.
All tests were performed on the Firefly Dx breadboard, which is
significantly faster than standard laboratory equipment and
protocols. A design advantage of Firefly Dx is that it does not
require additional equipment or separate steps for sample
preparation and purification, unlike current lab-based equipment,
thus reducing time to results as well as cost per test. In
addition, there is significantly less chance of sample
contamination compared to existing testing methods.
PositiveIDs Firefly Dx is designed to provide real-time,
accurate diagnostic results in a handheld device, thereby leading
to treatment scenarios at the point of need that are not possible
with existing systems, which require lab-based equipment, highly
trained personnel, and can take hours or even days to provide
results. Fireflys applications include point-of-need, lab-quality,
detection of pathogenic organisms; agricultural screening in both
domestic sectors and developing countries; and detection of
biological agents associated with weapons of mass destruction.
We are very pleased with our progress with the testing and
optimization of Firefly Dx, and are confident that with continued
development success, we will be able to deliver a real-time PCR
system that can revolutionize point-of-need biological detection
from an ease of use, time and cost perspective, stated William J.
Caragol, Chairman and CEO of PositiveID.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and
developer of biological detection systems for Americas homeland
defense industry as well as rapid biological testing. PositiveID is
focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in
order to detect biological threats and analyze biological samples.
For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on
Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the
likelihood that Firefly Dx is designed to provide real-time,
accurate diagnostic results in a handheld device, thereby leading
to treatment scenarios at the point of need that are not possible
with existing systems, which require lab-based equipment, highly
trained personnel, and can take hours or even days to provide
results; the likelihood that that with continued development
success, the Company will be able to deliver a real-time PCR system
that can revolutionize point-of-need biological detection from an
ease of use, time and cost perspective; constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Litigation Reform Act of 1995.
Such forward-looking statements involve risks and uncertainties and
are subject to change at any time, and PositiveID's actual results
could differ materially from expected results. These risks and
uncertainties include, without limitation, the Companys ability to
target the bio-threat detection and rapid medical testing sectors;
the Companys ability to complete the development of its Firefly Dx
system; as well as other risks. Additional information about these
and other factors that could affect the Company's business is set
forth in the Company's various filings with the Securities and
Exchange Commission, including those set forth in the Company's
10-K filed on March 30, 2015, and 10-Qs filed on May 15, 2015,
November 17, 2014, and August 14, 2014, under the caption "Risk
Factors." The Company undertakes no obligation to update or release
any revisions to these forward-looking statements to reflect events
or circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by law.
Contact:
PositiveID Corporation
Allison Tomek
(561) 805-8044
atomek@positiveidcorp.com
Investor Relations
Circadian Group
(647) 930-1037